Clinical trials: Urinary
Female Stress Urinary Incontinence
Clinical Evaluation of Ajust™ in Stress Urinary Incontinence
The purpose of this study is to assess the overall effectiveness of the Ajust Adjustable Single-Incision Sling in the surgical treatment of female stress urinary incontinence.
- Trial name
- CEASe (NCT01290796)
- Testing
- Ajust Adjustable Single-Incision Sling
- Where
- 6 sites in United States
- Volunteers
- 153 people
- Sponsor
- C. R. Bard
Urinary Bladder, Overactive
UK Study Assessing Flexible Dose Fesoterodine in Adults
To explore the effects of fesoterodine when used in a flexible dose manner
- Trial name
- SAFINA (NCT00806494)
- Testing
- Fesoterodine
- Where
- 39 sites in United Kingdom
- Volunteers
- 331 people
- Sponsor
- Pfizer
Postoperative Urinary Tract Infection, Pelvic Organ Prolapse
Gentamicin Intravesical Efficacy for Infection of Urinary Tract
Urinary tract infection (UTI) is a common problem after surgery for pelvic organ prolapse and stress urinary incontinence. This prospective, randomized, single-masked (subject), two-parallel armed study aims to determine the…
- Conditions
- Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
- Trial name
- GIVEIT (NCT04246996)
- Testing
- gentamicin sulfate, Catheter clamping only
- Where
- 2 sites in United States
- Volunteers
- 370 people
- Sponsor
- Kaiser Permanente
Benign Prostatic Hyperplasia
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the potential predictive value of the absence of prostate cancer in the treatment of patients with LUTS/BPH and an elevated serum PSA level.
- Trial name
- NCT01678313
- Testing
- Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD)
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Pain, Urinary Stone
Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal
This is a prospective randomized double-blind controlled trial assessing the benefits of intramuscular ketorolac before or immediately after office ureteral stent removal.
- Conditions
- Pain, Urinary Stone, Urinary Calculi
- Trial name
- NCT04112160
- Testing
- Ketorolac, normal saline
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Texas Southwestern Medical Center
Urinary Incontinence, Urgency Urinary
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary incontinence (UI) is a very common condition affecting women of all ages. The objective of this pilot study is to better understand the urinary microbiome and associated inflammatory markers in blood and urine in women…
- Trial name
- NCT04090190
- Testing
- Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Cystitis, Interstitial
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary…
- Trial name
- NCT00999518
- Testing
- Tanezumab
- Where
- 171 sites in United States, Belgium and 12 more
- Volunteers
- 205 people
- Sponsor
- Pfizer
Urinary Tract Infections
Seven vs. 14 Days Treatment for Male Urinary Tract Infection
This study will investigate the treatment of urinary tract infection in men. Specifically, the investigators are looking to see if shorter duration of antibiotics (7 days) is any worse than longer duration of antibiotics (14…
- Trial name
- NCT01994538
- Testing
- Longer therapy duration, Shorter therapy duration
- Where
- 2 sites in United States
- Volunteers
- 273 people
- Sponsor
- VA Office of Research and Development
Urinary Incontinence
Lessening Incontinence Through Low-impact Activity
The LILA study is a pilot randomized parallel-group trial of a group-based yoga therapy program versus physical conditionin control program for treatment of urinary incontinence in ambulatory middle-aged and older women.
- Trial name
- LILA (NCT02342678)
- Testing
- Yoga Therapy, Physical Conditioning
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Overactive Bladder
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index…
- Trial name
- NCT01737684
- Testing
- Vibegron
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Stress Urinary Incontinence
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical…
- Trial name
- NCT00998790
- Testing
- American Medical Systems (AMS) AdVance™ Male Sling System
- Where
- 3 sites in Belgium, France
- Volunteers
- 114 people
- Sponsor
- Boston Scientific Corporation
Bladder Cancer
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Study participants will have been diagnosed with bladder cancer that has invaded the muscle wall of the bladder. Surgery is used to remove cancer when it is in the muscle of the bladder.
- Trial name
- NCT00585689
- Testing
- ABI-007, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Urinary Incontinence, Stress
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
The purpose of the study is to determine if the administration of liposomal bupivacaine at the completion of a suburethral sling procedure will result in decreased postoperative pain compared to no injection.
- Trial name
- NCT02296099
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- TriHealth Inc.
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Genitourinary System; Disorder, Female, Burning Vagina
Laser Therapy for Treatment of Urogenital Symptoms in Women
This is a prospective observational study of women undergoing vaginal treatment with the fractional carbon dioxide (fCO2) laser for various urogenital symptoms.
- Conditions
- Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina
- Trial name
- NCT03681678
- Testing
- fCO2 Laser Therapy Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Corewell Health East
Bladder Cancer, URINARY BLADDER
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients.
- Trial name
- NCT00714948
- Testing
- gemcitabine and cisplatin plus sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.